A Randomized, Double‐Blind, Placebo‐Controlled, Twelve‐Week, Dose‐Ranging Study of Decernotinib, an Oral Selective JAK‐3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis

Published on Feb 1, 2015in Arthritis & Rheumatism9.586
· DOI :10.1002/ART.38949
Roy Fleischmann57
Estimated H-index: 57
(UTSW: University of Texas Southwestern Medical Center),
Nemanja Damjanov30
Estimated H-index: 30
(University of Belgrade)
+ 3 AuthorsN. Kinnman4
Estimated H-index: 4
Sources
Abstract
Objective To assess the efficacy and safety of oral decernotinib (VX-509; Vertex Pharmaceuticals) monotherapy in a 12-week, randomized, double-blind, placebo-controlled, dose-ranging study of patients with rheumatoid arthritis (RA). Methods Two hundred four adults with active RA who had been unsuccessfully treated with ≥1 disease-modifying antirheumatic drug were administered placebo tablets or decernotinib twice a day at dosages of 25 mg, 50 mg, 100 mg, or 150 mg. Primary measures of efficacy at week 12 were the response rate according to the American College of Rheumatology 20% improvement criteria (ACR20) and mean change from baseline in the Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP). Results At week 12, the ACR20 response rates were 39.0%, 61.0%, 65.0%, and 65.9% in the 25-mg, 50-mg, 100-mg, and 150-mg groups, respectively, and were significantly higher in the 50-mg group (P = 0.007) and the 100-mg and 150-mg groups (P = 0.002) as compared to the response rates in the placebo group (29.3%). The mean change from baseline in DAS28-CRP was greater in the 50-mg, 100-mg, and 150-mg groups as compared to the placebo group (P < 0.001). Decernotinib treatment resulted in higher ACR50 and ACR70 response rates, more patients with DAS28-CRP scores <2.6, and improvements in the Health Assessment Questionnaire disability index as compared to placebo. The most common adverse events in any decernotinib group were nausea (6.1%), headache (4.3%), an increase in levels of alanine aminotransferase (4.3%), and hypercholesterolemia (3.7%). In the groups receiving decernotinib, there was an increased risk of infections and increased liver transaminase levels. Conclusion Decernotinib was efficacious in improving clinical signs and symptoms of RA at week 12 at dosages of 50–150 mg twice a day. Infections and increases in liver transaminase and lipid levels were noted as potential safety signals.
Download
📖 Papers frequently viewed together
568 Citations
63 Citations
401 Citations
References28
Newest
#1John J. O'Shea (NIH: National Institutes of Health)H-Index: 113
#2Apostolos Kontzias (NIH: National Institutes of Health)H-Index: 5
Last. Arian Laurence (NIH: National Institutes of Health)H-Index: 50
view all 5 authors...
Biological therapies directed at proinflammatory cytokines have irrevocably changed the landscape of treatment of rheumatoid arthritis (RA) and other autoimmune diseases. With the advances in our knowledge in cytokine signalling, the question emerges whether targeting intracellular signalling might also be a safe and efficacious strategy. Janus kinases or Jaks are critical for a large family of cytokines and the first Jak inhibitors has been approved by the FDA. It is therefore timely to conside...
213 CitationsSource
#1Gerd R Burmester (Charité)H-Index: 79
#1G.-R. Burmester (Charité)H-Index: 44
Last. Charles A Mebus (Pfizer)H-Index: 11
view all 14 authors...
Summary Background Rheumatoid arthritis is a heterogeneous chronic disease, and no therapeutic agent has been identified which is universally and persistently effective in all patients. We investigated the effectiveness of tofacitinib (CP-690,550), a novel oral Janus kinase inhibitor, as a targeted immunomodulator and disease-modifying therapy for rheumatoid arthritis. Methods We did a 6-month, double-blind, parallel-group phase 3 study at 82 centres in 13 countries, including North America, Eur...
425 CitationsSource
#1Vasileios C. Kyttaris (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 35
The outlook for patients with rheumatoid arthritis has improved significantly over the last three decades with the use of disease-modifying antirheumatic drugs. However, despite the use of methotrexate, cytokine inhibitors, and molecules targeting T and B cells, a percentage of patients do not respond or lose their response over time. The autoimmune process in rheumatoid arthritis depends on activation of immune cells, which utilize intracellular kinases to respond to external stimuli such as cy...
62 CitationsSource
#1Ronald F. van Vollenhoven (KI: Karolinska Institutet)H-Index: 63
#1Ronald van Vollenhoven (Pfizer)H-Index: 9
Last. Bethanie WilkinsonH-Index: 15
view all 14 authors...
Background Tofacitinib (CP-690,550) is a novel oral Janus kinase inhibitor that is being investigated for the treatment of rheumatoid arthritis. Methods In this 12-month, phase 3 trial, 717 patients who were receiving stable doses of methotrexate were randomly assigned to 5 mg of tofacitinib twice daily, 10 mg of tofacitinib twice daily, 40 mg of adalimumab once every 2 weeks, or placebo. At month 3, patients in the placebo group who did not have a 20% reduction from baseline in the number of sw...
575 CitationsSource
At month 3, a higher percentage of patients in the tofacitinib groups than in the placebo groups met the criteria for an ACR 20 response (59.8% in the 5-mg tofacitinib group and 65.7% in the 10-mg tofacitinib group vs. 26.7% in the combined placebo groups, P<0.001 for both comparisons). The reductions from baseline in HAQ-DI scores were greater in the 5-mg and 10-mg tofacitinib groups than in the placebo groups (−0.50 and −0.57 points, respectively, vs. −0.19 points; P<0.001). The percentage of ...
568 CitationsSource
#1Edward C. Keystone (Radboud University Nijmegen)H-Index: 1
#2Josef Smolen (Radboud University Nijmegen)H-Index: 1
Last. P.L.C.M. van Riel (Radboud University Nijmegen)H-Index: 65
view all 3 authors...
RA is defined by the interrelated triad of disease activity, joint damage and disability. Although disease activity and its associated disability are reversible, joint damage and its associated disability are not. Thus, an important goal of RA therapy is to maximally reduce disease activity and thereby mitigate the accumulation of irreversible joint damage. Treatment for patients with RA should be initiated early and aggressively, with frequent assessments and a goal of achieving remission as qu...
32 CitationsSource
#1Yoshiya Tanaka (University of Occupational and Environmental Health Japan)H-Index: 70
#1Yoshiya Tanaka (University of Occupational and Environmental Health Japan)H-Index: 37
Last. Kunihiro YamaokaH-Index: 24
view all 3 authors...
Multiple cytokines play a pivotal role in the pathogenesis of rheumatoid arthritis (RA). The appropriate intracellular signalling pathways must be activated via cytokine receptors on the cell surface, and the tyrosine kinases transduce the first ‘outside to in’ signals to be phosphorylated after receptor binding to its ligand. Among them, members of the Janus kinase (JAK) family are essential for the signalling pathways of various cytokines and are implicated in the pathogenesis of RA. The in vi...
46 CitationsSource
#1Roy Fleischmann (UTSW: University of Texas Southwestern Medical Center)H-Index: 57
#2Maurizio Cutolo (UniGe: University of Genoa)H-Index: 57
Last. Samuel H. Zwillich (Pfizer)H-Index: 28
view all 12 authors...
Objective To compare the efficacy, safety, and tolerability of 5 doses of oral tofacitinib (CP-690,550) or adalimumab monotherapy with placebo for the treatment of active rheumatoid arthritis (RA) in patients with an inadequate response to disease-modifying antirheumatic drugs. Methods In this 24-week, double-blind, phase IIb study, patients with RA (n = 384) were randomized to receive placebo, tofacitinib at 1, 3, 5, 10, or 15 mg administered orally twice a day, or adalimumab at 40 mg injected ...
273 CitationsSource
#1David T. Felson (University of Manchester)H-Index: 139
#2Josef S. Smolen (Medical University of Vienna)H-Index: 27
Last. Maarten Boers (VU: VU University Amsterdam)H-Index: 67
view all 44 authors...
Objective Remission in rheumatoid arthritis (RA) is an increasingly attainable goal, but there is no widely used defi nition of remission that is stringent but achievable and could be applied uniformly as an outcome measure in clinical trials. This work was undertaken to develop such a defi nition. Methods A committee consisting of members of the American College of Rheumatology, the European League Against Rheumatism, and the Outcome Measures in Rheumatology Initiative met to guide the process ...
300 CitationsSource
#1Jackie L Nam (University of Leeds)H-Index: 17
#2Kevin L. Winthrop (OHSU: Oregon Health & Science University)H-Index: 57
Last. Maya H Buch (University of Leeds)H-Index: 37
view all 11 authors...
Objectives To review the evidence for the efficacy and safety of biological agents in patients with rheumatoid arthritis (RA) to provide data to develop treatment recommendations by the European League Against Rheumatism (EULAR) Task Force. Methods Medline, Embase and Cochrane databases were searched for relevant articles on infliximab (IFX), etanercept (ETN), adalimumab (ADA), certolizumab-pegol (CZP), golimumab (GLM), anakinra (ANA), abatacept (ABT), rituximab (RTX) and tocilizumab (TCZ) publi...
397 CitationsSource
Cited By69
Newest
JAKs are a family of intracellular tyrosine kinases consisting of four members, JAK1, JAK2, JAK3, and TYK2. They are key components of the JAK-STAT pathway that transmit signals of many cytokines involved in the pathogenesis of numerous immune-mediated diseases and have been major molecular targets in developing new drugs for the treatment of such diseases. Some small-molecule inhibitors of JAKs have been approved by the FDA for rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel d...
Source
#1Andreas Kerschbaumer (University of Vienna)H-Index: 7
#1Andreas Kerschbaumer (University of Vienna)
Last. Désirée van der Heijde (Loyola University Medical Center)H-Index: 22
view all 15 authors...
Source
#1Y.-K. Sung (Hanyang University)
#2Yun Hi Lee (KU: Korea University)H-Index: 19
Last. Young Ho Lee (KU: Korea University)H-Index: 52
view all 2 authors...
1 CitationsSource
#1Thomas El Jammal (Lyon College)H-Index: 4
#2Pascal Sève (Lyon College)H-Index: 38
Last. Yvan Jamilloux (Lyon College)H-Index: 21
view all 4 authors...
1 CitationsSource
Rheumatoid arthritis is a world leading cause of musculoskeletal disease. With the introduction of biological agents as treatment alternatives the clinical possibilities have grown exponentially. Currently most common Disease-modifying anti-rheumatic drugs (DMARDs) treatment option involves intravenous or subcutaneous injection, and some patients struggle to respond to DMARDs or lose their primary reaction. An oral drug formulation with lowered costs of manufacturing and flexibility for healthca...
2 CitationsSource
#1Jacopo Angelini (University of Milan)H-Index: 1
#2R. Talotta (UNIME: University of Messina)H-Index: 2
Last. Francesco Scaglione (University of Milan)H-Index: 32
view all 8 authors...
Janus kinase inhibitors (JAKi) belong to a new class of oral targeted disease-modifying drugs which have recently revolutionized the therapeutic panorama of rheumatoid arthritis (RA) and other immune-mediated diseases, placing alongside or even replacing conventional and biological drugs. JAKi are characterized by a novel mechanism of action, consisting of the intracellular interruption of the JAK-STAT pathway crucially involved in the immune response. The aim of this narrative review is to glob...
2 CitationsSource
#1Flavia Sunzini (Glas.: University of Glasgow)H-Index: 6
#1Flavia Sunzini (Glas.: University of Glasgow)H-Index: 1
Last. Stefan Siebert (Glas.: University of Glasgow)H-Index: 23
view all 3 authors...
Currently, there is a growing interest in Janus kinase (JAK) intracellular signalling since targeted inhibitors against these pathways are proving effective in the treatment of a range of immune-me...
Source
#2Nemanja DamjanovH-Index: 30
Last. Jean Beebe (Pfizer)H-Index: 13
view all 14 authors...
OBJECTIVE: This Phase 2a, 8-week, double-blind, parallel-group study evaluated the efficacy and safety of PF-06651600 (ritlecitinib), an irreversible inhibitor of Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family, versus placebo, in patients with rheumatoid arthritis (RA). METHODS: Seventy patients, seropositive for anticitrullinated protein antibodies and/or rheumatoid factor, were randomized 3:2 to receive oral PF-06651600 (200 mg once dail...
2 CitationsSource
#1Andreas Kerschbaumer (Medical University of Vienna)H-Index: 7
#2Josef S Smolen (Medical University of Vienna)H-Index: 83
Last. Daniel Aletaha (Medical University of Vienna)H-Index: 68
view all 6 authors...
Phase 3 trials are the mainstay of drug development across medicine but have often not met expectations set by preceding phase 2 studies. A systematic meta-analysis evaluated all randomized controlled, double-blind trials investigating targeted disease-modifying anti-rheumatic drugs in rheumatoid and psoriatic arthritis. Primary outcomes of American College of Rheumatology (ACR) 20 responses were compared by mixed-model logistic regression, including exploration of potential determinants of effi...
1 CitationsSource
#1Massimo Gadina (NIH: National Institutes of Health)H-Index: 45
#2Danielle A. Chisolm (NIH: National Institutes of Health)H-Index: 1
Last. John J. O'Shea (NIH: National Institutes of Health)H-Index: 113
view all 6 authors...
The discovery of JAKs and STATs and their roles in cytokine and IFN action represented a significant basic advance and a new paradigm in cell signaling. This was quickly followed by discoveries pointing to their essential functions, including identification of JAK3 mutations as a cause of SCID. This and other findings predicted the use of therapeutically targeting JAKs as a new strategy for treating immune and inflammatory diseases. This now is a reality with seven approved jakinibs being used t...
1 CitationsSource